

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

9516-335-999
(501872-999496)

APPLICATION NO.

10/590,575

APPLICANT:

Zeldis

FILING DATE

August 22, 2006

GROUP

1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	60/607,408		Muller et al.			9/3/04
	A02	60/454,149		Man et al.			3/12/03
	A03	60/452,460		Muller et al.			3/5/03
	A04	60/452,374		Zeldis et al.			3/6/03
	A05	60/438,450		Muller et al.			1/7/03
	A06	60/438,448		Muller et al.			1/7/03
	A07	10/934,974		Muller et al.			9/3/04
	A08	10/900,332		Muller et al.			7/28/04
	A09	10/900,270		Muller et al.			7/28/04
	A10	10/798,372		Man et al.			3/12/04
	A11	10/798,317		Man et al.			3/12/04
	A12	10/794,931		Muller et al.			3/5/04
	A13	10/748,085		Man et al.			12/29/03
	A14	2004/0167199	8/26/04	Muller et al.			
	A15	20030187052	10/2/03	Muller et al.			
	A16	6,699,899	3/2/04	Man et al.			
	A17	6,667,316	12/23/03	Man et al.			
	A18	6,518,281	2/11/03	Muller et al.			
	A19	6,479,554	11/12/02	Muller et al.			
	A20	6,429,221	8/6/02	Muller et al.			
	A21	6,326,388	12/4/01	Man et al.			
	A22	6,284,780	9/4/01	Muller et al.			
	A23	6,262,101	7/17/01	Muller et al.			
	A24	6,214,857	4/10/01	Muller et al.			
	A25	6,200,987	3/13/01	Muller			
	A26	6,180,644	1/30/01	Muller et al.			
	A27	6,130,226	10/10/00	Muller et al.			
	A28	6,075,041	6/13/00	Muller			
	A29	6,046,221	4/4/00	Muller et al.			
	A30	6,020,358	2/1/00	Muller et al.			
	A31	6,011,050	1/4/00	Muller et al.			
	A32	5,968,945	10/19/99	Muller et al.			
	A33	5,929,117	7/27/99	Muller et al.			
	A34	5,877,200	3/2/99	Muller			
	A35	5,801,195	9/1/98	Muller et al.			
	A36	5,736,570	4/7/98	Muller et al.			

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

9516-335-999
(501872-999496)

APPLICATION NO.

10/590,575

APPLICANT:

Zeldis

FILING DATE

August 22, 2006

GROUP

1617

	A37	5,728,845	3/17/98	Muller et al.			
	A38	5,728,844	3/17/98	Muller et al.			
	A39	5,703,098	12/30/97	Muller et al.			
	A40	5,698,579	12/16/97	Muller			
	A41	5,658,940	8/19/97	Muller et al.			
	A42	5,605,914	2/25/97	Muller			
	A43	5,463,063	10/31/95	Muller			
	A44	5,134,127	7/28/92	Stella et al.			
	A45	2003/0185826	10/2/03	Tobinick			
	A46	2003/0113318	6/19/03	Tobinick			
	A47	2003/0049256	3/13/03	Tobinick			
	A48	2003/0007972	1/9/03	Tobinick			
	A49	2002/0131955	9/19/02	Tobinick			
	A50	2002/0131954	9/19/02	Tobinick			
	A51	2002/0054899	5/9/02	Zeldis			
	A52	2001/0026801	10/4/01	Tobinick			
	A53	2001/0016195	8/23/01	Tobinick			
	A54	2001/0004456	6/21/01	Tobinick			
	A55	6,623,736	9/23/03	Tobinick			
	A56	6,537,549	3/25/03	Tobinick			
	A57	6,471,961	10/29/02	Tobinick			
	A58	6,428,787	8/6/02	Tobinick			
	A59	6,423,321	7/23/02	Tobinick			
	A60	6,419,944	7/16/02	Tobinick			
	A61	6,419,934	7/16/02	Tobinick			
	A62	6,379,666	4/30/02	Tobinick			
	A63	6,297,286	10/2/01	Huckle			
	A64	6,177,077	1/23/01	Tobinick			
	A65	6,015,557	1/18/00	Tobinick et al.			
	A66	5,929,117	7/27/99	Muller et al.			
	A67	5,877,200	3/2/99	Muller			
	A68	5,739,119	4/14/98	Galli et al.			
	A69	5,698,579	12/16/97	Muller			
	A70	5,434,170	7/18/95	Andrulis			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 03/080048	10/2/03	PCT				
	B02	WO 03/080049	10/2/03	PCT				

	B03	WO 01/45702	6/28/01	PCT				
	B04	WO 01/34606	5/17/01	PCT				
	B05	WO 99/06041	2/11/99	PCT				
	B06	WO 97/23457	7/3/97	PCT				
	B07	WO 97/08143	3/6/97	PCT				
	B08	WO 95/01348	1/12/95	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Akaike et al., 1993, "Rolipram enhances the development of voltage-dependent Ca ²⁺ current and serotonin-induced current in rat pheochromocytoma cells," Brain Res. 620(1):58-63
	C02	Auluck et al., 2002, "Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease," Science 295(5556):865-868
	C03	Bancher et al., 1989, "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease," Brain Res. 477(1-2):90-99
	C04	Banta et al., 1977, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology 27(3):213-216
	C05	Baraitser, 1990, The Genetics of Neurological Disorders, 2 nd ed., pp. 85-88
	C06	Bourtchouladze et al., 2003, "A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4," Proc. Natl. Acad. Sci. USA 100(18):10518-10522
	C07	Calne et al., 1987, "Familial Parkinson's disease: possible role of environmental factors," Can. J. Neurol. Sci. 14(3):303-305
	C08	Caraceni et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression," Neurology 41(3):380-384
	C09	Casacchia et al., 1983, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334
	C10	Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301
	C11	Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl. I):1107-1113
	C12	Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80
	C13	Crook et al., 1986, Dev. Neuropsychol. 2:261-276
	C14	Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147
	C15	Freo et al., 2001, "Effects of Acetylcholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitmine," Soc. Neurosci. Abstr. 677.5
	C16	Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179
	C17	Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917
	C18	Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417
	C19	Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440
	C20	Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-228
	C21	Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379
	C22	Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104
	C23	Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773
	C24	Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104
	C25	Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260
	C26	Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68
	C27	Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429
	C28	Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197
	C29	McGeer et al., 2001, B.C. Med. J. 43:138-141
	C30	Merritt, 1979, A Textbook of Neurol., 6 th ed., Lea & Febiger, Philadelphia, pp. 484-489
	C31	Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490
	C32	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg. Med. Chem. Lett. 9(11):1625-1630

C33	Nussbaum et al., 1997, "Genetics of Parkinson's disease," Hum. Mol. Genet. 6(10):1687-1691
C34	Olson, 2000, "Biomedicine. Combating Parkinson's disease--step three," Science 290(5492):721-724
C35	Parkes et al., 1984, "Rolipram in Parkinson's disease," Adv. Neurol. 40:563-565
C36	Petersen et al., 2001, "Current concepts in mild cognitive impairment," Arch. Neurol. 58(12):1985-1992
C37	Petersen et al., 1999, "Mild cognitive impairment: clinical characterization and outcome," Arch. Neurol. 56(3):303-308
C38	Petersen et al., 1995, "Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals," JAMA 273(16):1274-1278
C39	Polymeropoulos et al., 1996, "Mapping of a gene for Parkinson's disease to chromosome 4q21-q23," Science 274(5290):1197-1199
C40	Price et al., 1999, "Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease," Ann. Neurol. 45(3):358-368
C41	Rabe et al., 1982, "Enhancement of depolarization-dependent neurosecretion from PC12 cells by forskolin-induced elevation of cyclic AMP," J. Cyclic. Nucleotide Res. 8(6):371-384
C42	Rousselet et al., 2002, "Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP," Exp. Neurol. 177(1):183-192
C43	Sriram et al., 2002, "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease," FASEB J. 16(11):1474-1476
C44	Takahashi et al., 1999, "Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms," J. Neurosci. 19(2):610-618
C45	Traynor et al., 1984, "Phospholipases elevate cyclic AMP levels and promote neurite extension in a clonal nerve cell line," Dev. Brain Res. 316(2):197-204
C46	Troncoso et al., 1996, "Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging," Neurobiol. Aging 17(3):365-371
C47	Westlund et al., 1992, "Effects of nerve growth factor and acetyl-L-carnitine arginyl amide on the human neuronal line HCN-1A," Int. J. Dev. Neurosci. 10(5):361-373
C48	Wolff, ed., 1995, I Burger's Medicinal Chemistry and Drug Discovery, 5 th ed., pp. 172-178 and 949-982
C49	Wolozin et al., 1987, "Alzheimer-related neuronal protein A68: specificity and distribution," Ann. Neurol. 22(4):521-526
C50	Zhu et al., 2001, "The antidepressant and antiinflammatory effects of rolipram in the central nervous system," CNS Drug Rev. 7(4):387-398
C51	Engelhart et al., 2002, "Dietary intake of antioxidants and risk of Alzheimer Disease," J. Am. Med. Assoc. 287(24):3223-3229
C52	Foley et al., 2002, "Dietary intake of antioxidants and risk of Alzheimer Disease," J. Am. Med. Assoc. 287(24):3261-3263
C53	Morris et al., 2002, "Dietary intake of antioxidant nutrients and the risk of incident Alzheimer Disease in a biracial community study," J. Am. Med. Assoc. 287(24):3230-3237
C54	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," Bioorg. Med. Chem. Lett. 8(19):2669-2674
C55	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240
C56	Physician's Desk Reference, 2002, 56 th ed., pp. 1755-1760
C57	Saha et al., 2003, "Tumor necrosis factor- α at the crossroads of neuronal life and death during HIV-associated dementia," J. Neurochem. 86:1057-1071
C58	Wolff ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5 th ed. 172-178, 949-982
C59	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-673
C60	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," Crit. Rev. Immunol. 22(5-6):425-437
C61	DREDGE et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," Br. J. Cancer 87(10):1166-1172
C62	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," Expert Opin. Biol. Ther. 2(8):953-966
C63	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," Cancer Res. 63(23):8073-8078
C64	MARRIOTT et al., 2001, "Immunotherapeutic and antitumor potential of thalidomide analogues," Expert Opin. Biol. Ther. 1(4):1-8
C65	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," Clin. Exp. Immunol. 130(1):75-84
C66	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," Br. J. Haematol. 124(3):366-375
C67	ZELDIS et al., 2003, "Potential new therapeutics for Waldenstrom's macroglobulinemia," Semin. Oncol. 30(2):275-281

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.